Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States

Author： Lingappa J.R.   Rosenstein N.   Zell E.R.   Shutt K.A.   Schuchat A.   Perkins B.A.   Active Bacterial Core Surveillance ABCs Team  

Publisher： Elsevier

ISSN： 0264-410X

Source： Vaccine, Vol.19, Iss.31, 2001-08, pp. : 4566-4575

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain

By Salleras L.   Domnguez A.   Cardenosa N.  

Vaccine, Vol. 21, Iss. 7, 2003-01 ,pp. : 725-728

Elsevier

Access to resources Recommend Favorite

Meningococcal disease in primary care: reducing the risk of error

By Cowan Jane   Kavanagh Sean  

Clinical Governance: An International Journal, Vol. 10, Iss. 2, 2005-06 ,pp. : 175-182

Emerald Group Publishing Ltd

Access to resources Recommend Favorite

Vaccine prevention of meningococcal disease, coming soon?

By Morley S.L.   Pollard A.J.  

Vaccine, Vol. 20, Iss. 5, 2001-12 ,pp. : 666-687

Elsevier

Access to resources Recommend Favorite

Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease

By Aase A.   Naess L.M.   Sandin R.H.   Herstad T.K.   Oftung F.   Holst J.   Haugen I.L.   Hoiby E.A.   Michaelsen T.E.  

Vaccine, Vol. 21, Iss. 17, 2003-05 ,pp. : 2051-2060

Elsevier

Access to resources Recommend Favorite

The effectiveness of serogroup C meningococcal vaccine estimated from routine surveillance data

By Rivest P.   Allard R.  

Vaccine, Vol. 20, Iss. 19, 2002-06 ,pp. : 2533-2536

Elsevier

Access to resources Recommend Favorite